Io­vance's $211M of­fer­ing; Almi­rall li­cens­es No­vo drug; As­traZeneca files Da­to-DXd; Sonata lay­offs

Plus oth­er news you may have missed from the FTC, Ever­est, Gilead, IsomAb, Oramed, In­novent, Sonata, Lari­mar and Im­munome.

Io­vance Bio­ther­a­peu­tics of­fers $211M in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER